vEAET-H for Chronic Pain Patients Using Medical Cannabis in Israel - A Feasibility Study (NCT07732062) | Clinical Trial Compass
RecruitingNot Applicable
vEAET-H for Chronic Pain Patients Using Medical Cannabis in Israel - A Feasibility Study
Israel42 participantsStarted 2026-10-01
Plain-language summary
The goal of this clinical trial is to evaluate whether a culturally adapted, virtual, group-based emotional therapy called Emotional Awareness and Expression Therapy is feasible and whether it can help reduce chronic pain and improve emotional well-being among Israeli adults who suffer from chronic musculoskeletal pain and are treated with medical cannabis.
Participants will attend a weekly 1.5-hour virtual group therapy session for 8 weeks, except for the first session, which will be held in-person at the hospital's clinic. The participants will take part in group discussions and emotional processing exercises, complete questionnaires about pain levels, mood, sleep, and quality of life, and continue their usual medical treatment as prescribed by their doctors.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Diagnosed with any chronic musculoskeletal pain (≥ three months in duration) including back, neck, limb or pelvic pain, tension headache and fibromyalgia;
. Treated with medical Cannabis;
. Physical and mental ability to participate in group discussions;
. Fluent in reading and speaking Hebrew.
Exclusion criteria
. Chronic pain conditions not classified as chronic primary pain. These include neuropathies such as carpal or tarsal tunnel syndrome, radiculopathy, and neuralgia;
. Primary headache disorders such as cluster headaches;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Brief Pain Inventory (BPI) - 4 items of pain severity
Timeframe: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
. Autoimmune diseases typically associated with pain, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, and sickle cell disease;
. Inflammatory systemic diseases causing pain, including osteoarthritis or gout.
. Severe mental illness or psychiatric disorder such as schizophrenia, bipolar I disorder, multiple personality disorder, or dissociative identity disorder not controlled with medications, active suicide or violence risk in the past year, active severe alcohol or substance use disorder, self-reported use of intravenous drugs.
. Participant with a significant negative life event within the past six months, such as the death of a close person, significant loss of income, or another traumatic or highly stressful event, which may substantially affect the participant's emotional state, safety, or ability to participate in the intervention;